News|Videos|November 19, 2026

Single Annual Injection Produces Significant and Sustained Lp(a) Reductions

Fact checked by: Ryan Livingston

Kausik Ray, MD, MBChB, MPhil, discusses recent results from a trial of the investigational siRNA SRSD216, targeting Lp(a) on a cellular level.

SRSD216, a novel siRNA targeting lipoprotein(a) (Lp(a)), maintained Lp(a) reductions of 85% at the highest dose of 600 mg for up to 1 year after a single injection, according to 2 analyses of a recent study.1,2

These data were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, by Kausik Ray, MD, MBChB, MPhil, professor of public health at Imperial College London and director of the Imperial Centre for Cardiovascular Disease Prevention.1,2

“We’re already into phase 2 looking at these particular doses, and it looks like the durability is going to be 1 year,” Ray told HCPLive in an exclusive interview. “So, the dosing interval should follow – the next dose will be at 1 year.”

SRSD216 is a double-stranded siRNA, specifically designed to modulate the LPA gene – this, in turn, decreases hepatic Apo(a) production and reduces circulating Lp(a). Preclinical studies have demonstrated SRSD216’s high target specificity and a clean safety profile, while an earlier phase 1 study has shown dose-dependent activity, Lp(a) reductions of ≤95%, and no meaningful safety signals after a single dose.3

The present study was a double-blind, placebo-controlled, randomized, dose-escalation phase 1 trial investigating SRSD216 in Chinese men or women aged 18-55 years with Lp(a) levels ≥75 nmol/L. The primary endpoint was safety and tolerability, while secondary endpoints included pharmacokinetics and Lp(a) change from baseline over time. Pharmacodynamic (PD) samples were collected every 1-2 weeks within 2 months after the first and only dose, and then monthly thereafter for the rest of the year.1,2

A total of 24 patients were enrolled at a single Chinese center, who were then split into 3 cohorts comprising 8 patients each. These patients were randomly assigned 6:2 to receive either SRSD216 or placebo, with the former evaluated at 3 separate doses (100, 300, and 600 mg). All 18 patients assigned to the 3 SRSD216 doses and 6 patients assigned to placebo completed the full 1-year follow-up. The mean age among these patients was 37.6 +/- 8.5 years, and 54.2% were male. Patients had a baseline Lp(a) of 107 +/- 46 nmol/L.1,2

During the year of follow-up, Ray and colleagues saw more frequent treatment-emergent adverse events (TEAEs) reported among patients receiving SRSD216, with incidences of 83.3% in the 100 mg cohort, 50% in the 300 mg cohort, and 83.3% in the 600 mg cohort, compared with 16.7% in the placebo cohort. Each of these was categorized as Grade 1 or 2 in severity, and no serious AEs or AEs leading to death or withdrawal occurred during the study.1,2

Of these AEs, injection site reactions occurred in 22.2% of SRSD216 recipients. Upper respiratory tract infection occurred in 16.7% of the SRSD216 cohort and in 16.7% of the placebo cohort. Additionally, 2 patients in the treatment cohorts had concurrent ALT and AST elevations without increases in bilirubin, which resolved over the course of follow-up.1,2

A single dose of SRSD216, according to Ray and colleagues, produced dose-dependent Lp(a) reductions of ≤95% by day 43 in the 300 mg and 600 mg cohorts, with annualized time-averaged reductions of 85% for both arms. Additionally, this reduction showed very little month-to-month within-person variability over 1 year versus placebo.1,2

Ultimately, the team determined that SRSD216’s tolerability, coupled with its efficacy in reducing Lp(a), established it as a prime target for further research. Annual dosing of 600 mg could provide reductions comparable to several other medications, which require substantially more frequent dosing. Ray points out that, despite ongoing studies, these data may take longer to externally validate in other populations.1,2

“The problem with SRSD216 is that, because of the long duration, you’ve got to wait that much longer to see if you can start the second dose, and whether that’s still going to work,” Ray said. “By default, you have to have a longer follow-up, but that’s quite good as well because you get additional safety data.”

Editors’ Note: Ray reports disclosures with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Regeneron, and others.

References
  1. Ray K, Gu L, Yue P, et al. SRSD216 a Once Yearly Novel Small Interfering RNA Therapeutic to Lipoprotein(a) Provides Time Averaged Annualized Reduction of 85% After a Single Dose - A Phase 1 Study. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.
  2. Ray K, Gu L, Li W, et al. MDP0860 - SRSD216 a Novel siRNA Therapeutic Provides Sustained Durable Reductions in Lipoprotein(a) up to 1 Year After a Single Dose- A Phase 1 Dose-Escalation Study. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.
  3. Sirius Therapeutics. SRSD216 Demonstrates Sustained Lp(a) Reduction and Favorable Safety Profile in Phase 1 Trial. March 31, 2026. Accessed November 19, 2026. https://www.siriusrna.com/html/companynews/118.html

Related to this article